| Heart disease and stroke statistics—2013 update: a report from the American Heart Association AS Go, D Mozaffarian, VL Roger, EJ Benjamin, JD Berry, WB Borden, ... circulation 127 (1), e6-e245, 2013 | 58260* | 2013 |
| The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels FM Sacks, MA Pfeffer, LA Moye, JL Rouleau, JD Rutherford, TG Cole, ... New England Journal of Medicine 335 (14), 1001-1009, 1996 | 10153 | 1996 |
| 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on … RA Nishimura, CM Otto, RO Bonow, BA Carabello, JP Erwin, RA Guyton, ... Journal of the American College of Cardiology 63 (22), e57-e185, 2014 | 9782* | 2014 |
| Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial MA Pfeffer, E Braunwald, LA Moyé, L Basta, EJ Brown Jr, TE Cuddy, ... New England journal of medicine 327 (10), 669-677, 1992 | 7689 | 1992 |
| 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines DC Goff Jr, DM Lloyd-Jones, G Bennett, S Coady, RB D’agostino, ... Circulation 129 (25_suppl_2), S49-S73, 2014 | 7469 | 2014 |
| Intensive versus moderate lipid lowering with statins after acute coronary syndromes CP Cannon, E Braunwald, CH McCabe, DJ Rader, JL Rouleau, R Belder, ... New England journal of medicine 350 (15), 1495-1504, 2004 | 6728 | 2004 |
| Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High … MJ Sarnak, AS Levey, AC Schoolwerth, J Coresh, B Culleton, LL Hamm, ... Circulation 108 (17), 2154-2169, 2003 | 5914 | 2003 |
| Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. MA Pfeffer, E Braunwald Circulation 81 (4), 1161-1172, 1990 | 4428 | 1990 |
| Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial S Yusuf, MA Pfeffer, K Swedberg, CB Granger, P Held, JJV McMurray, ... The Lancet 362 (9386), 777-781, 2003 | 3847 | 2003 |
| Cardiac-resynchronization therapy for the prevention of heart-failure events AJ Moss, WJ Hall, DS Cannom, H Klein, MW Brown, JP Daubert, ... New England Journal of Medicine 361 (14), 1329-1338, 2009 | 3687 | 2009 |
| Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both MA Pfeffer, JJV McMurray, EJ Velazquez, JL Rouleau, L Køber, ... New England Journal of Medicine 349 (20), 1893-1906, 2003 | 3414 | 2003 |
| AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood … SC Smith Jr, J Allen, SN Blair, RO Bonow, LM Brass, GC Fonarow, ... Circulation 113 (19), 2363-2372, 2006 | 3141 | 2006 |
| Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials BPLT Trialists’Collaboration, F Turnbull Lancet 362 (9395), 1527-1535, 2003 | 3141 | 2003 |
| Spironolactone for heart failure with preserved ejection fraction B Pitt, MA Pfeffer, SF Assmann, R Boineau, IS Anand, B Claggett, ... New England Journal of Medicine 370 (15), 1383-1392, 2014 | 2852 | 2014 |
| Renin–angiotensin–aldosterone system inhibitors in patients with Covid-19 M Vaduganathan, O Vardeny, T Michel, JJV McMurray, MA Pfeffer, ... New England Journal of Medicine 382 (17), 1653-1659, 2020 | 2736 | 2020 |
| Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial JJV McMurray, J Östergren, K Swedberg, CB Granger, P Held, ... The Lancet 362 (9386), 767-771, 2003 | 2713 | 2003 |
| C-reactive protein levels and outcomes after statin therapy PM Ridker, CP Cannon, D Morrow, N Rifai, LM Rose, CH McCabe, ... New England Journal of Medicine 352 (1), 20-28, 2005 | 2693 | 2005 |
| Lixisenatide in patients with type 2 diabetes and acute coronary syndrome MA Pfeffer, B Claggett, R Diaz, K Dickstein, HC Gerstein, LV Køber, ... New England Journal of Medicine 373 (23), 2247-2257, 2015 | 2669 | 2015 |
| Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM … CB Granger, JJV McMurray, S Yusuf, P Held, EL Michelson, B Olofsson, ... The Lancet 362 (9386), 772-776, 2003 | 2647 | 2003 |
| Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme MA Pfeffer, K Swedberg, CB Granger, P Held, JJV McMurray, ... The Lancet 362 (9386), 759-766, 2003 | 2641 | 2003 |
